Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.
- 25 Apr 2016 Planned End Date changed from 1 Apr 2020 to 1 Jun 2019.